Yang, Yuan
Ge, Hongmin
Wang, Xijin
Liu, Xuejun
Li, Keqing
Wang, Gang
Yang, Xiaodong
Deng, Huaili
Sun, Meijuan
Zhang, Ruiling
Chen, Jindong
Cai, Duanfang
Sang, Hong
Liu, Xianglai
Zhan, Guilai
Zhao, Guijun
Li, Haiyun
Xun, Zhiyuan
Clinical trials referenced in this document:
Documents that mention this clinical trial
Safety and effectiveness of oral medium to high dose blonanserin in patients with schizophrenia: subgroup analysis from a prospective, multicenter, post-marketing surveillance study in mainland China
https://0-doi-org.brum.beds.ac.uk/10.1186/s12991-023-00467-w
Article History
Received: 31 May 2023
Accepted: 22 September 2023
First Online: 6 October 2023
Declarations
:
: The study protocols were approved by the ethics committees of the leading clinical site at the Second Xiangya Hospital of Central South University (ethics approval number 2018-093). With the exception of individual clinical sites that approved waivers, all patients signed the informed consent form. The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.
: HY Li is an employee of Sumitomo Pharma (Suzhou) Co., Ltd. Other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.